Iovance Biotherapeutics
IOVA
273 hedge funds and large institutions have $3.22B invested in Iovance Biotherapeutics in 2024 Q1 according to their latest regulatory filings, with 70 funds opening new positions, 90 increasing their positions, 83 reducing their positions, and 33 closing their positions.
199% more call options, than puts
Call options by funds: $93.8M | Put options by funds: $31.4M
112% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 33
87% more capital invested
Capital invested by funds: $1.72B → $3.22B (+$1.5B)
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
16% more funds holding
Funds holding: 236 → 273 (+37)
8% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 83
4.69% less ownership
Funds ownership: 82.47% → 77.78% (-4.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$84.9M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$58.2M |
| 3 |
MFM
MHR Fund Management
New York
|
+$46.6M |
| 4 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
+$34.5M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$34.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$70.1M |
| 2 |
Morgan Stanley
New York
|
-$55.2M |
| 3 |
O
OrbiMed
New York
|
-$38.3M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$31.7M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$23.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AWM
301
AE Wealth Management
Topeka,
Kansas
| – | -$79.5K | -10,478 | Closed |
|
302
Belvedere Trading
Chicago,
Illinois
| – | -$50.3K | -4,323 | Closed |
|
|
BWM
303
BKM Wealth Management
Brookfield,
Wisconsin
| – | -$4.63K | -570 | Closed |
|
|
GWS
304
Glassman Wealth Services
Vienna,
Virginia
| – | -$951 | -117 | Closed |
|
|
C
305
Covestor
London,
United Kingdom
| – | -$116 | -10 | -50% |
|
|
SA
306
Scarborough Advisors
Annapolis,
Maryland
| – | -$49 | -6 | Closed |
|
IOVA Hedge Fund Activity: Q1 2024 in Review
273 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2024, worth a combined $3.22B — up 87% from $1.72B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new IOVA positions and 33 closed out — a net gain of 37 holders — while 90 added to existing stakes and 83 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $84.9M. The largest seller was State Street, cutting an estimated $70.1M.
- 273 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2024, up from 236 in Q4 2023.
- Funds reported $3.22B of Iovance Biotherapeutics stock for Q1 2024, up 87% quarter-over-quarter.
- 70 funds opened new Iovance Biotherapeutics positions in Q1 2024 and 33 closed out, a net change of +37 holders.
- The largest Iovance Biotherapeutics buyer in Q1 2024 was Perceptive Advisors, an estimated $84.9M added.
- The largest Iovance Biotherapeutics seller in Q1 2024 was State Street, an estimated $70.1M sold.
Based on aggregated 13F filings for Q1 2024.